Investigation for renewal treatment strategy for small cell lung cancer: Imaging biomarker of neutropenia in amrubicin treatment

2015 Fiscal Year Final Research Report

• Project/Area Number: 25870610
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Medical pharmacy; Tumor therapeutics
• Research Institution: Nagoya City University
• Principal Investigator: Takakuwa Osamu 名古屋市立大学, 医学(系)研究科(研究院), 助教 (10647332)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 小細胞肺癌 / 抗癌剤治療 / 一塩基多型 / アムルビシン

Outline of Final Research Achievements

Aim of this study is to find a clinical biomarker for amrubicin treatment and its mechanism. We found that polymorphisms of ABCB1 have relationship with amrubicin-induced neutropenia. Also, we had a result that area under the plasma concentration versus time curve (AUC) values of amrubicinol have a significant relation with grade of neutropenia during amrubicin treatment. However, we could not reach to identify the factor which regulates AUC value of amrubicinol. We now focus on organic cation transporter (OCT) and have continued to investigate factors which regulate pharmacological function of amrubicin.

Free Research Field

肺癌化学療法